Cancer is a disease that presents significant emotional, social, economic and clinical problems worldwide. Globally, in 2018, there were 17 million new cancer cases, and 9.6 million cancer deaths, with this burden predicted to increase significantly in coming years, highlighting the need for research into more effective treatment options.

Cancer research within the School of Pharmacy and Biomolecular Sciences aims to progress a precision oncology paradigm by understanding the molecular drivers of malignant disease, discovering rational therapeutic targets, and identifying key biomarkers to define disease progression and treatment outcome.

We are focused on a range of tumours, mainly breast, ovarian, colorectal, oesophageal and lung. Some of our programmes are funded through the SFI Strategic Partnership Programme Precision Oncology Ireland – a consortium of five Irish universities, six Irish cancer research charities and seven international companies aiming to develop new diagnostics and therapeutics for personalised cancer treatment. Other major funding streams include SFI Frontiers for the Future Programme (FFP), Career Development Award (CDA) and Starting Investigator Research Grant (SIRG); the National Children's Research Centre (NCRC), the EU, Susan G. Komen and World Cancer Research Fund International (WCRF).

Meet our researchers